Longevity as a Commodity
Last week, GlaxoSmithKline announced it will buy Sirtris Pharmaceuticals for US$720 million, giving weight to the claim that antiaging biotech firms can be a good bet. This is good news for Americans, given that a recent Harvard-affiliated study showed that